Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Seynaeve

Showing results (51-60 of 175) with videos related to

Pageof 18
Sort By:
Psycho-Oncology|March 1, 2007
The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective studyIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2006
Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testingIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trialChristina M Schilder, Caroline Seynaeve, Louk V Beex, et al.
Patient Education and Counseling|July 29, 2006
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distressIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
Cancer|November 21, 2012
The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counselingPeggy M L H Vencken, Mieke Kriege, Maartje Hooning, et al.
Human Pathology|December 20, 2014
Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancerVictorien M T van Verschuer, Maartje J Hooning, Radka D van Baare-Georgieva, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 10, 2016
Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevantWillemina R R Geurts-Giele, Victorien M T van Verschuer, Carolien H M van Deurzen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology studyVicky S Sabine, Cheryl Crozier, Cassandra L Brookes, et al.
Archives of Pathology & Laboratory Medicine|December 31, 2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical TrialJohn M S Bartlett, Jason Christiansen, Mark Gustavson, et al.
Plos One|May 5, 2012
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer riskStian Knappskog, Liv B Gansmo, Pål Romundstad, et al.
Pageof 18

Showing results (51-60 of 175) with videos related to

Sort By:
Pageof 18
Psycho-Oncology|March 1, 2007
The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective studyIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2006
Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testingIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trialChristina M Schilder, Caroline Seynaeve, Louk V Beex, et al.
Patient Education and Counseling|July 29, 2006
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distressIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
Cancer|November 21, 2012
The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counselingPeggy M L H Vencken, Mieke Kriege, Maartje Hooning, et al.
Human Pathology|December 20, 2014
Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancerVictorien M T van Verschuer, Maartje J Hooning, Radka D van Baare-Georgieva, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 10, 2016
Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevantWillemina R R Geurts-Giele, Victorien M T van Verschuer, Carolien H M van Deurzen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology studyVicky S Sabine, Cheryl Crozier, Cassandra L Brookes, et al.
Archives of Pathology & Laboratory Medicine|December 31, 2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical TrialJohn M S Bartlett, Jason Christiansen, Mark Gustavson, et al.
Plos One|May 5, 2012
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer riskStian Knappskog, Liv B Gansmo, Pål Romundstad, et al.
Pageof 18